Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran
,
Abstract
Background: Hairy cell leukemia (HCL) is a chronic B-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect. The study aims to evaluate a group of patients with hairy cell leukemia, hospitalized in the Clinic of Hematology and Oncology, Kermanshah, Iran, on a period of 15 years and affect of between cladribine therapy and IFN therapy on the patients with HCL.
Methods: This is a retrospective analysis of 11 patients in the Clinic of Hematology and Oncology, Kermanshah, Iran, between 2004 and 2013. Clinical features at diagnosis, differential count (platelet, Hb and WBC) types of therapy, survival rate and BRAF mutation have been monitored. As a result, cladribine therapy is the best treatment option for patients.
Results: The mean age of patients was 50 years with 100% of men. Approximately 45% of them had splenomegaly at diagnosis. 100% of patients had pancytopenia at diagnosis.9% of patients had mutation of BRAF V600E. Before of treatment, there were fatigue, weight loss, vomiting, fever, night sweat and itching in all of the patients.
Conclusion: There is presence of hairy cells in peripheral blood and bone marrow and was associated with pancytopenia, splenomegaly, myelofibrosis in HCL patients. Also, cladribine therapy is best option for treatment of patients and it is better than IFN.
Găman AM. Hairy cell leukemia--a rare type of leukemia. A retrospective study on 39 patients. Rom J Morphol Embryol. 2013;54(3):575-9.
Shackelford RE, Heldmann M, Eskandari F, et al. Marked retroperitoneal lymphadenopathy in hairy cell leukemia: A case report. Case Rep Oncol. 2013 Sep 28;6(3):493-6.
Laurini JA, Aoun P, Iqbal J, et al. Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012 Dec;138(6):877-83.
Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012:660-6.
Cai B, Wang S, Huang J, et al. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res. 2013; 5(1):36-46.
Maevis V, Mey U, Schmidt-Wolf G, et al. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J. 2014 Feb 14; 4:e184.
Morgan EA, Yu H, Pinkus JL, et al. Immunohistochemical detection of hairy cell leukemia in paraffin sections using a highly effective CD103 rabbit monoclonal antibody. Am J Clin Pathol. 2013 Feb;139(2):220-30.
Monterroso J, Chandana S. Images in clinical medicine. Massive splenomegaly in hairy-cell leukemia. N Engl J Med. 2012 Nov 29;367(22):2133.
Pande P, Yelikar BR, Kumar U M. A hairy cell leukaemia variant - a rare case report.J Clin Diagn Res. 2013 Feb; 7(2):358-60.
Galani KS, Subramanian PG, Gadage VS, et al. Clinico- pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol. 2012 Jan-Mar; 55(1):61-5.
Pande P, Yelikar BR, Kumar U M. A hairy cell leukaemia variant - a rare case report. J Clin Diagn Res. 2013 Feb;7(2):358-60.
Chatterjee T, Panigrahi I, Mahapatra M, et al. Hairy cell leukemia: clinical, pathological and ultrastructural findings in Asian-Indians. Indian J Cancer. 2008 Apr-Jun; 45(2):41-4.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949–54.
Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol; 2010.80:561–7.
Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review) Oncol Rep. 2009;22:671–81.
Kamiguti AS, Harris RJ, Slupsky JR, et al. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene. 2003; 22:2272–84.
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 Jun 16; 364(24):2305-15.
Sigal DS, Miller HJ, Schram ED, et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood; 2010 Oct 21. 116(16):2884-96.
Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010 Mar 11; 115(10):1893-6.
Baker PK, Pettitt AR, Slupsky JR, et al. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood. 2002 Jul 15;100(2):647-53.
Steis RG, Smith JW, Urba WJ, et al. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood. 1991 Feb 15;77(4):792-8.
Lauria F, Zinzani PL, Raspadori D, et al. Relationship between immunological phenotype and hematological response to alpha-IFN treatment in 35 patients with hairy cell leukemia. Eur J Haematol Suppl. 1990;52:3-6.
Damasio EE, Frassoldati A. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma. 1994;14 Suppl 1:95-8.
| Files | ||
| Issue | Vol 9, No 3 (2015) | |
| Section | Articles | |
| Keywords | ||
| Cladribine y Cell Leukemia Splenomegaly | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
